NanoViricides, Inc. (AMEX:NNVC) was founded in 2005 and is headquartered in Shelton, Connecticut, USA. It has 7 full-time employees. It is a nano-biopharmaceutical company that discovers, develops and commercializes nano-therapeutics for the treatment of viral infections.
NanoViricides, Inc. (NNVC):
NanoViricides is a development stage company with unique nanomedicine technology. The company is developing bionic antiviral drugs based on nanotechnology, which the company calls “nanoviricides®”. The company develops virus-specific nanokiller candidates for five commercially important viral diseases, including: seasonal and potentially epidemic influenza and avian influenza, HIV/AIDS, cold sores and genital herpes infections, viral eye diseases, and dengue fever The virus has proven to be very effective.
NanoViricides is developing anti-influenza drug candidates in the preclinical and advanced preclinical stages, including:
- Two FluCide drugs: 1) NV-INF-2, an oral anti-flu drug; NV-INF-1, an injectable anti-flu drug for H7N9, avian influenza H5N1 and other highly pathogenic influenza.
- HIVCide, an anti-human immunodeficiency virus (HIV) drug candidate, can provide functional treatment for HIV/AIDS.
- HerpeCide, a skin cream or gel formulation used to treat oral and genital herpes virus infections.
- Eye drops fight against viral infections of the outer eye, and participate in other research projects against rabies virus, Ebola virus and Marburg virus.